Davis Polk & Wardwell Advised AC Immune SA On $80 Million Stock Offering
Davis Polk & Wardwell Advised AC Immune SA On $80 Million Stock Offering
Davis Polk & Wardwell LLP advised AC Immune SA on its SEC-registered at-the-market offering of common stock for up to $80 million. The common stock is listed on the Nasdaq Global Market under the symbol ACIU.
AC Immune SA, headquartered in Lausanne, Switzerland, is a clinical-stage biopharmaceutical company specializing in precision medicine for neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases, as well as NeuroOrphan indications associated with misfolded proteins. The company employs two clinically validated technology platforms, SupraAntigen and Morphomer, to drive its diverse pipeline, which includes 16 therapeutic and diagnostic programs. Among these, five are in Phase 2 clinical trials and one is in Phase 3.
The Davis Polk corporate team was led by Partner Derek Dostal and included Associates Katie Warshauer and Sakiko Nishida.
The tax team comprised Counsel Alon Gurfinkel and associate Kelli A. Rivers.
Associates Harrison Perry and Nausherwan Ahmed Aamir provided advice on the Investment Company Act. Members of the Davis Polk team were based in the New York and London offices.
